Core Insights - STRATA Skin Sciences, Inc. reported a modest revenue increase of 1% year-over-year for Q1 2025, totaling $6.8 million, with gross margins improving significantly by nearly 800 basis points to 53.5% [6][10][24] - The company has successfully executed its direct-to-consumer strategy, resulting in a 32% increase in unique psoriasis patients and a 128% increase in unique acne patients compared to the prior year [4] - International revenue grew by 8% in Q1 2025, contributing to 36% of total revenue, and is expected to continue growing as global tariff uncertainties resolve [5] Financial Performance - Revenue for Q1 2025 was $6.8 million, a 1% increase from Q1 2024, with global recurring revenue at $4.7 million and equipment revenue at $2.1 million, both up approximately 1% [6][10] - Gross profit for Q1 2025 was $3.6 million, representing 53.5% of revenue, compared to $3.1 million or 45.6% of revenue in Q1 2024 [6][24] - Total operating expenses decreased by 5% to $5.7 million, with significant reductions in engineering and product development expenses by 60% [7][24] Loss and Cash Position - The net loss for Q1 2025 was $2.4 million, or a loss per share of $0.58, an improvement from a net loss of $3.4 million or $0.96 per share in Q1 2024 [7][24] - Cash, cash equivalents, and restricted cash at the end of Q1 2025 were $7.8 million, down from $8.6 million at the beginning of the period [8][26] Strategic Developments - The company is focused on enhancing its direct-to-consumer marketing efforts and building a strong franchise in dermatology and aesthetics [20] - STRATA's partnership program offers innovative treatment technologies with a fee-per-treatment cost structure, which is expected to drive further growth [19][18]

Core Insights - STRATA Skin Sciences, Inc. will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City [1] - Dr. Dolev Rafaeli, President and CEO, will host one-on-one meetings during the conference from 9:00 AM to 3:00 PM (ET) [2] Company Overview - STRATA Skin Sciences is focused on developing, commercializing, and marketing innovative products for treating dermatologic conditions such as psoriasis, vitiligo, and acne [3] - The company's product offerings include the XTRAC excimer laser, VTRAC lamp systems, and the TheraClearX Acne Therapy System [3] Partnership Program - STRATA offers a unique Partnership Program in the U.S., which includes a fee per treatment cost structure instead of requiring equipment purchase [4] - The program provides on-site training for practice personnel, service and maintenance of equipment, dedicated account and customer service associates, and co-op advertising support [4]

Core Viewpoint - STRATA Skin Sciences, Inc. will report its first quarter 2025 financial results on May 14, 2025, after market close [1] Group 1: Financial Results Announcement - The financial results will be followed by a conference call at 5:00 p.m. ET on the same day to review the results and provide updates on corporate developments [2] - Interested parties can join the conference call via domestic and international dialing options, with a recommendation to join 10 minutes early [3] Group 2: Replay Information - A telephonic replay of the call will be available until May 21, 2025, with specific dialing instructions provided [4] - A webcast replay will be accessible approximately one hour after the live call and will remain available until September 21, 2025 [4] Group 3: Company Overview - STRATA Skin Sciences is focused on developing and marketing innovative products for dermatologic conditions, including psoriasis, vitiligo, and acne [5] - The company offers products such as the XTRAC excimer laser, VTRAC lamp systems, and the TheraClearX Acne Therapy System [5] Group 4: Partnership Program - STRATA employs a unique Partnership Program that includes a fee per treatment cost structure, on-site training, service and maintenance, and co-op advertising support [6]